| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9377877 | Biological Psychiatry | 2005 | 7 Pages |
Abstract
In contrast to our earlier report of positive effects in bipolar disorder, these data suggest that the GR-antagonist mifepristone has no effect on neurocognitive function or symptoms in this group of patients with schizophrenia. Future studies in schizophrenia should examine patients with demonstrable hypothalmic-pituitary-adrenal axis dysfunction.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Peter Gallagher, Stuart Watson, Margaret S. Smith, Ian Nicol Ferrier, Allan H. Young,